Quantcast
Home > Quotes > NLNK

NewLink Genetics Corporation Common Stock (NLNK) Quote & Summary Data

NLNK 
$1.65
*  
0.02
1.2%
Get NLNK Alerts
*Delayed - data as of Apr. 24, 2019  -  Find a broker to begin trading NLNK now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 1.69 / $ 1.62
Share Volume
262,370
50 Day Avg. Daily Volume
580,748
Previous Close
$ 1.67
52 Week High / Low
$ 5.61 / $ 1.2775
Market Cap
61,505,568
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
262,370
50 Day Avg. Daily Volume:
580,748

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.44

Trading Range

The current last sale of $1.65 is 29.16% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.69 $ 5.61
 Low: $ 1.62 $ 1.2775

Company Description (as filed with the SEC)

NewLink Genetics Corporation (the "Company", "NewLink", "we", "our" or "us") is a clinical-stage immuno-oncology company focused on developing novel immunotherapeutic products for the treatment of patients with cancer. Our leading small-molecule product candidates currently in clinical development target the indoleamine-2, 3-dioxygenase, or IDO, pathway, which is one of the key pathways for cancer immune escape. These product candidates, indoximod and NLG802 (a prodrug of indoximod), are IDO pathway inhibitors with mechanisms of action that center around breaking the immune system's tolerance to cancer. We also have an additional small molecule product candidate, NLG207, which is a nanoparticle-drug conjugate, or NDC, consisting of a cyclodextrin-based polymer backbone linked to camptothecin, a topoisomerase 1 inhibitor of the topoisomerase-1 inhibitor, camptothecin.  ... More ...  



Risk Grade

Where does NLNK fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.67
Open Date:
Apr. 24, 2019
Close Price:
$ 1.65
Close Date:
Apr. 24, 2019


Consensus Recommendation

Analyst Info